---
name: NEPHRIX Biosolutions
slug: nephrix-biosolutions
site: cro
website_domain: nephrix-biosolutions.com
summary: Specialized preclinical CRO offering in vitro and in vivo kidney disease models, histology services, and biomarker analysis for renal and fibrotic disease drug development. Headquartered in Labège, France.
tagline: Kidney disease preclinical CRO with exclusive expertise in renal and fibrotic disease models.
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: FR
tier2_domain_verified: false
updated_at: 2026-08-08T07:01:27.509Z
services_count: 7
modalities_count: 0
indications_count: 2
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# NEPHRIX Biosolutions

Kidney disease preclinical CRO with exclusive expertise in renal and fibrotic disease models.

Listed on cro.directory.

## Summary

Specialized preclinical CRO offering in vitro and in vivo kidney disease models, histology services, and biomarker analysis for renal and fibrotic disease drug development. Headquartered in Labège, France.

## At a glance

- HQ country: FR

## Services

- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Pathology & Histology Services
- Bioanalysis
- Biomarker Assays

## Indications

- Nephrology
- Rare Disease

## Locations

- Headquarters, Labège, Occitanie, France

## Long description

NEPHRIX Biosolutions is a preclinical contract research organization focused exclusively on kidney and fibrotic disease research. The company provides a full range of in vitro and in vivo preclinical services including validated rodent models, human primary cell assays, and high-quality histology with quantitative digital pathology.

**In Vitro Services:**
- Fibrosis assays using human primary fibroblasts from renal, lung, cardiac, and skin origins
- Inflammation assays
- Senescence assay platform with human primary cells from various tissue origins
- DuoXProx renal co-culture model
- Nephrotoxicity screening on human-derived cells

**In Vivo Models:**
- Ischemia Reperfusion Injury (IRI) kidney model
- Unilateral Ureteral Obstruction (UUO) model
- Streptozotocin (STZ) diabetic nephropathy models in rats and mice
- IgA nephropathy model
- Adenine-induced kidney disease model
- Surgical models with validated ethical procedures on mice and rats

**Additional Capabilities:**
- Biomarker analysis and bioanalysis platform to assess therapeutic efficacy, safety, and mechanism of action
- Histology expertise in fibrosis, inflammation, nephrotoxicity, and aging
- Fast study initiation with adaptable study designs
- Commitment to ethical practices and 3Rs principles

## Related companies

- [BioLegacy Research](/companies/biolegacy) (Preclinical In Vitro Studies, Preclinical In Vivo Studies) — [Compare](/compare/biolegacy/nephrix-biosolutions)
- [ITR Laboratories](/companies/itrlab) (Preclinical In Vitro Studies, Preclinical In Vivo Studies) — [Compare](/compare/itrlab/nephrix-biosolutions)
- [Biotest Facility](/companies/bioxpedia) (Preclinical In Vitro Studies, Preclinical In Vivo Studies) — [Compare](/compare/bioxpedia/nephrix-biosolutions)
- [Champions Oncology](/companies/championsoncology) (Preclinical In Vitro Studies, Preclinical In Vivo Studies) — [Compare](/compare/championsoncology/nephrix-biosolutions)
- [Nucro-Technics](/companies/nucro-technics) (Preclinical In Vitro Studies, In Vitro Pharmacology) — [Compare](/compare/nephrix-biosolutions/nucro-technics)
- [Axxam](/companies/axxam) (Preclinical In Vitro Studies, In Vitro Pharmacology) — [Compare](/compare/axxam/nephrix-biosolutions)
- [JangoCell](/companies/jangocell) (Preclinical In Vitro Studies, In Vitro Pharmacology) — [Compare](/compare/jangocell/nephrix-biosolutions)
- [ChemPartner](/companies/chempartner) (Preclinical In Vitro Studies, Preclinical In Vivo Studies) — [Compare](/compare/chempartner/nephrix-biosolutions)

_Profile last updated: 2026-08-08T07:01:27.509Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.